Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals

Methylation levels of the mitochondrial displacement loop (D-loop) region have been reported to be altered in the brain and blood of Alzheimer’s disease (AD) patients. Moreover, a dynamic D-loop methylation pattern was observed in the brain of transgenic AD mice along with disease progression. However, investigations on the blood cells of AD patients in the prodromal phases of the disease have not been performed so far. The aim of this study was to analyze D-loop methylation levels by means of the MS-HRM technique in the peripheral blood cells of 14 mild cognitive impairment (MCI) patients, 18 early stage AD patients, 70 advanced stage AD patients, and 105 healthy control subjects. We found higher D-loop methylation levels in MCI patients than in control subjects and AD patients. Moreover, higher D-loop methylation levels were observed in control subjects than in AD patients in advanced stages of the disease, but not in those at early stages. The present pilot study shows that peripheral D-loop methylation levels differ in patients at different stages of AD pathology, suggesting that further studies deserve to be performed in order to validate the usefulness of D-loop methylation analysis as a peripheral biomarker for the early detection of AD.

[1]  Seongju Lee,et al.  Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers , 2022, Biomedicines.

[2]  Sareesh Naduvil Narayanan,et al.  Epigenetic Mechanisms in Memory and Cognitive Decline Associated with Aging and Alzheimer’s Disease , 2021, International Journal of Molecular Sciences.

[3]  J. Waring,et al.  Association of peripheral blood DNA methylation level with Alzheimer’s disease progression , 2021, Clinical Epigenetics.

[4]  C. Masters,et al.  The Amyloid-β Pathway in Alzheimer’s Disease , 2021, Molecular Psychiatry.

[5]  S. Papageorgiou,et al.  APOE Genotype and Alzheimer's Disease: The Influence of Lifestyle and Environmental Factors. , 2021, ACS chemical neuroscience.

[6]  F. Coppedè,et al.  Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson’s Disease Patients , 2021, Genes.

[7]  Sang Ryong Kim,et al.  Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease , 2021, International journal of molecular sciences.

[8]  F. Coppedè,et al.  Mitochondrial DNA Methylation and Human Diseases , 2021, International journal of molecular sciences.

[9]  Yingying Xu,et al.  Hypermethylation of Mitochondrial Cytochrome b and Cytochrome c Oxidase II Genes with Decreased Mitochondrial DNA Copy Numbers in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease , 2021, Neurochemical Research.

[10]  N. Larsson,et al.  Mitochondrial DNA copy number in human disease: the more the better? , 2020, FEBS letters.

[11]  J. Dudley,et al.  Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicate its dynamic role in disease progression , 2020, Clinical epigenetics.

[12]  A. Murray,et al.  DNA methylation analysis of candidate genes associated with dementia in peripheral blood. , 2020, Epigenomics.

[13]  Li Rong,et al.  Mitochondrial gene COX2 methylation and downregulation is a biomarker of aging in heart mesenchymal stem cells , 2020, International journal of molecular medicine.

[14]  F. Coppedè,et al.  Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis , 2020, Clinical epigenetics.

[15]  Zina M. Ibrahim,et al.  An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene , 2020, Neurobiology of Aging.

[16]  J. Waring,et al.  Harnessing peripheral DNA methylation differences in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease , 2020, Clinical Epigenetics.

[17]  Wenzhang Wang,et al.  Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances , 2020, Molecular Neurodegeneration.

[18]  D. Perani,et al.  CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  J. Fessel.  The paradox of opposite directions of gene expressions in MCI and AD suggests possible therapy to prevent progression of MCI to AD , 2020, Alzheimer's & dementia.

[20]  H. Byun,et al.  Elevated serum mitochondrial DNA in females and lack of altered platelet mitochondrial methylation in patients with Parkinson´s disease , 2020, The International journal of neuroscience.

[21]  H. Hampel,et al.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases , 2020, Expert review of molecular diagnostics.

[22]  H. Cui,et al.  Mitoepigenetics and Its Emerging Roles in Cancer , 2020, Frontiers in Cell and Developmental Biology.

[23]  F. Jessen,et al.  Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood , 2019, Clinical Epigenetics.

[24]  J. Bi,et al.  Altered mitochondrial DNA methylation and mitochondrial DNA copy number in an APP/PS1 transgenic mouse model of Alzheimer disease. , 2019, Biochemical and biophysical research communications.

[25]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[26]  R. Swerdlow,et al.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities , 2019, British journal of pharmacology.

[27]  M. Esteller,et al.  Clinical epigenetics: seizing opportunities for translation , 2018, Nature Reviews Genetics.

[28]  F. Coppedè,et al.  Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. , 2018, Epigenomics.

[29]  Ying Cheng,et al.  The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease , 2018, Front. Neurosci..

[30]  R. Swerdlow.  Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[31]  U. Bonuccelli,et al.  A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting , 2017, Neurological Sciences.

[32]  K. Blennow.  A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood , 2017, Neurology and Therapy.

[33]  Magda Tsolaki,et al.  Mitochondrial genes are altered in blood early in Alzheimer's disease , 2017, Neurobiology of Aging.

[34]  A. Hoffman,et al.  Mitochondrial DNA Hypomethylation Is a Biomarker Associated with Induced Senescence in Human Fetal Heart Mesenchymal Stem Cells , 2017, Stem cells international.

[35]  C. Cotman,et al.  Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease , 2016, Alzheimer's & Dementia.

[36]  R. Youle,et al.  The Mitochondrial Basis of Aging. , 2016, Molecular cell.

[37]  M. Capogrossi,et al.  Methylation profiling by bisulfite sequencing analysis of the mtDNA Non-Coding Region in replicative and senescent Endothelial Cells. , 2016, Mitochondrion.

[38]  B. Pickard,et al.  Quantification of global mitochondrial DNA methylation levels and inverse correlation with age at two CpG sites , 2016, Aging.

[39]  A. Beaudet,et al.  Epigenetics and Human Disease. , 2016, Cold Spring Harbor perspectives in biology.

[40]  M. Barrachina,et al.  Altered Mitochondrial DNA Methylation Pattern in Alzheimer Disease-Related Pathology and in Parkinson Disease. , 2016, The American journal of pathology.

[41]  Shunichiro Shinagawa,et al.  Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer’s Disease and Amnesic Mild Cognitive Impairment , 2016, PloS one.

[42]  M. Memo,et al.  Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients , 2016, Oxidative medicine and cellular longevity.

[43]  S. Sengupta,et al.  Mitoepigenetics: The different shades of grey. , 2015, Mitochondrion.

[44]  P. D’Aquila,et al.  Age-and gender-related pattern of methylation in the MT-RNR1 gene. , 2015, Epigenomics.

[45]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[46]  C. Cotman,et al.  Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease , 2014, Neurobiology of Aging.

[47]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[48]  M. Lovell,et al.  Epigenetic changes in the progression of Alzheimer's disease , 2013, Mechanisms of Ageing and Development.

[49]  L. Martin,et al.  Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS , 2013, Front. Cell. Neurosci..

[50]  W. M. van der Flier,et al.  Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI , 2013, Neurology.

[51]  H. Manev,et al.  Effect of aging on 5-hydroxymethylcytosine in brain mitochondria , 2012, Neurobiology of Aging.

[52]  S. Zehetmayer,et al.  The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia , 2012, International Psychogeriatrics.

[53]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[54]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[55]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[56]  A. Mitchell,et al.  Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies , 2009, Acta psychiatrica Scandinavica.

[57]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[58]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[59]  R. Swerdlow.  The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease. , 2020, International review of neurobiology.

[60]  F. Coppedè,et al.  Decreased Methylation of the Mitochondrial D-Loop Region in Late-Onset Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[61]  Shunjiang Xu,et al.  Elevation of Peripheral BDNF Promoter Methylation Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Longitudinal Study. , 2017, Journal of Alzheimer's disease : JAD.

[62]  L. Higgins,et al.  A Transgenic Mouse Model of Alzheimer’s Disease , 1994 .